Clinical Guest Contributors

  1. Helus Shares Experience Studying Adjunctive Psychedelic For Major Depressive Disorder 6/26/2026

    Helus Pharma CMO Amir Inamdar discusses the strategic rationale behind its Phase 3 trial for major depressive disorder, including its adjunctive-treatment approach, patient population selection, and endpoint strategy.

  2. Understanding And Preserving Data Flow Integrity In AI-Assisted Clinical Trials 6/26/2026

    Learn from ex-FDA and ELIQUENT consultant Dawn Wydner, Ph.D.., how treating data integrity as an end-to-end clinical information flow issue, rather than a database-only concern, is essential to managing AI-related risk.

  3. RWE Increasingly Supports Rare Disease Research As RCTs Alone Fall Short 6/25/2026

    Chiesi's Rachele Berria, MD, Ph.D., discusses how RWE is reshaping rare disease drug development strategies, from leveraging registries and patient-reported outcomes to navigating evolving regulatory expectations.

  4. AI Can Help Design Better Trials, But It Still Can't Tell You Whether Patients Will Join Them 6/25/2026

    AI is changing the way clinical trial trials are discussed, planned, and designed. But even with an improved protocol, are AI-enhanced trials driving better enrollment?

  5. Will AI And Agile Project Management Help Advance RBM? 6/24/2026

    Will AI-based tools embedded into risk based-monitoring prompt an Agile project management moment for clinical research? Sidharth Ananthanarayan explains why AI-based tools are not the answer but part of it.

  6. The Next Chapter Of Obesity And Type 2 Diabetes Care: ADA 2026 Signals A More Personalized Future 6/23/2026

    The American Diabetes Association 2026 conference showed where we are and where we're going with GLP-1 therapies.

  7. Why Building Long-Term Value And Making Clinical Progress Are Inextricable 6/23/2026

    Dicot Pharma CEO Elin Trampe discusses how clinical milestones, financing strategy, shareholder value, and partnering considerations must be tightly integrated in early development through late-stage planning. 

  8. What Sponsors Don't See: The Systems Behind Clinical Trial Delivery 6/22/2026

    What do sponsors need from sites? Easy. How do they evaluate them? Not so easy (or accurate). In this column, Association Multisite Research Corporations (AMRC) Executive Director Jim Kremidas explains how sites and sponsors can make site evaluations better.

  9. What Really Happens At The Site When Sponsors Pull Back Mid-Trial 6/19/2026

    When sponsors slow or reduce operational spending due to financial pressure, strategic pivots, or internal restructuring, sites — and patients — suffer. Curo Research CCO Amy Bland explains how sponsors can better manage operational changes.

  10. A Sponsor Playbook For Matching AI Use Cases To Readiness, Risk, And ROI 6/18/2026

    Clinical technology consultant Karen Maduschke explains why your next AI investment should solve a problem you can articulate, with data you can access, in a process you can change.